Dexamethasone: 0.15mg/kg/dose PO or IV (Max 6 mg/dose) once daily for up to 10 days or until discharge from hospital, if sooner.
For patients on dexamethasone, AND within 14 days of new COVID-19 diagnosis with evidence of cytokine release syndrome/HLH.
On a case-by-case basis where there is evidence of worsening disease such as, increasing oxygen or ventilator requirement and/or evidence of systemic inflammation (e.g. elevated CRP), immunomodulatory agents such as tocilizumab and anakinra may be considered under expert guidance from specialist teams
Management considerations for CRS/secondary HLH and related inflammatory clinical entities secondary to COVID-19: